Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 6 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 16 patents granted in the last 365 days
Kymera Therapeutics Inc. has 8 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 8 distinct examiners and 6 distinct art units, showing broad examiner distribution across several technical examination groups.
CHANDRAKUMAR, NIZAL S is the busiest examiner, with 1 pending matter. The data does not identify a dominant examiner, so prosecution management should emphasize consistency in scientific disclosure and claim strategy across the docket.
The greater number of examiners than art units indicates that some examination groups contain matters assigned to different examiners. Counsel should monitor both dimensions when assessing recurring objections, amendment positions, and opportunities for coordinated responses.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (12%) |
| §112 only | 5 (62%) |
| Multi-statute (no §101) | 2 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHANDRAKUMAR, NIZAL S | 1 | 72.6% | +18.3% |
| SAMSELL, RILLA MARIE | 1 | 69.1% | +6.4% |
| MCDOWELL, BRIAN E | 1 | 74.0% | +31.3% |
| SEITZ, ANTHONY JOSEPH | 1 | 68.3% | +26.7% |
| RAO, SAVITHA M | 1 | 60.7% | +29.7% |
| YOO, SUN JAE | 1 | 70.9% | +1.0% |
| CHEN, PO-CHIH | 1 | 74.3% | +14.7% |
| SANCHEZ, JUSTIN CHRISTOPHER | 1 | 87.3% | +12.1% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17597631 | PROTEIN DEGRADERS AND USES THEREOF | SANCHEZ, JUSTIN CHRISTOPHER | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18453163 | CDK2 INHIBITORS AND USES THEREOF | SEITZ, ANTHONY JOSEPH | 8d overdue |
| 18583347 | CRBN LIGANDS AND USES THEREOF | MCDOWELL, BRIAN E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18453163 | CDK2 INHIBITORS AND USES THEREOF | SEITZ, ANTHONY JOSEPH | 8d overdue |
| 18912154 | IRAK DEGRADERS AND USES THEREOF | CHANDRAKUMAR, NIZAL S | — |
| 18583347 | CRBN LIGANDS AND USES THEREOF | MCDOWELL, BRIAN E | — |
| 18002116 | IRAK DEGRADERS AND USES THEREOF | RAO, SAVITHA M | — |
| 17597628 | FUSED-GLUTARIMIDE CRBN LIGANDS AND USES THEREOF | CHEN, PO-CHIH | — |
| 17597631 | PROTEIN DEGRADERS AND USES THEREOF | SANCHEZ, JUSTIN CHRISTOPHER | — |
| Art Unit | Apps |
|---|---|
| 1624 | 2 |
| 1621 | 2 |
| 1625 | 1 |
| 1629 | 1 |
| 1691 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18912154 | IRAK DEGRADERS AND USES THEREOF | CHANDRAKUMAR, NIZAL S | 1625 | §112 | Non-Final OA | — | Pending | Oct 10, 2024 |
| 18704633 | TYK2 DEGRADERS AND USES THEREOF | SAMSELL, RILLA MARIE | 1624 | §112 | Non-Final OA | — | Pending | Apr 25, 2024 |
| 18583347 | CRBN LIGANDS AND USES THEREOF | MCDOWELL, BRIAN E | 1624 | §102§112 | Non-Final OA | — | Pending | Feb 21, 2024 |
| 18453163 | CDK2 INHIBITORS AND USES THEREOF | SEITZ, ANTHONY JOSEPH | 1629 | §102§103§112 | Final Rejection | 8d overdue | Pending | Aug 21, 2023 |
| 18002116 | IRAK DEGRADERS AND USES THEREOF | RAO, SAVITHA M | 1691 | §112 | Non-Final OA | — | Pending | Dec 16, 2022 |
| 17997463 | IRAK INHIBITORS AND USES THEREOF | YOO, SUN JAE | 1621 | §112 | Final Rejection | — | Pending | Oct 28, 2022 |
| 17597628 | FUSED-GLUTARIMIDE CRBN LIGANDS AND USES THEREOF | CHEN, PO-CHIH | 1621 | §102 | Final Rejection | — | Pending | Jan 14, 2022 |
| 17597631 | PROTEIN DEGRADERS AND USES THEREOF | SANCHEZ, JUSTIN CHRISTOPHER | 1622 | §112 | Final Rejection | — | Pending | Jan 14, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKymera Therapeutics Inc. has 8 pending office actions as of November 2026, spread across 6 art units and 8 examiners.
Nizal S Chandrakumar has the most, with 1 of Kymera Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.